[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640970":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":7,"responsibleParty":18,"collaborators":7,"id":20,"slug":7,"hasResults":21,"nctId":22,"briefTitle":23,"officialTitle":24,"acronym":7,"eligibilityCriteria":25,"healthyVolunteers":21,"sex":26,"minAge":27,"maxAge":7,"enrollmentInfo":28,"targetDuration":31,"studyType":32,"phases":7,"briefSummary":33,"conditions":34,"keywords":7,"overallStatus":36,"whyStopped":7,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":7},{"fullName":5,"class":6},"Ipsen","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Ipsen Medical Director","STUDY_DIRECTOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Ipsen Clinical Study Enquiries","CONTACT","See e mail","clinical.trials@ipsen.com",{"type":19,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100640970",false,"NCT07585097","A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment","Prospective Non-Interventional Study Evaluating the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS)","Inclusion Criteria:\n\n* Diagnosed with ALGS.\n* On (or starting) active odevixibat treatment.\n* Aged 6 months or older at the time of consent.\n\nExclusion Criteria:\n\n* Currently participating in a clinical trial with odevixibat.\n* Currently participating in any interventional clinical trial for ALGS.\n* Have any contraindication to odevixibat as per the locally approved label.","ALL","6 Months",{"count":29,"type":30},30,"ESTIMATED","2 Years","OBSERVATIONAL","This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching.\n\nThe main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.",[35],"Alagille Syndrome","NOT_YET_RECRUITING","2026-07-01",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":30},"2026-09-30",{"date":44,"type":30},"2031-09-30",{"name":5,"class":6}]